Complement activation cascade triggered by PEG–PL engineered nanomedicines and carbon nanotubes: The challenges ahead
Since their introduction, poly(ethylene glycol)–phospholipid (PEG–PL) conjugates have found many applications in design and engineering of nanosized delivery systems for controlled delivery of pharmaceuticals especially to non-macrophage targets. However, there are reports of idiosyncratic reactions...
Gespeichert in:
| Veröffentlicht in: | Journal of controlled release 2010-09, Vol.146 (2), p.175-181 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 181 |
|---|---|
| container_issue | 2 |
| container_start_page | 175 |
| container_title | Journal of controlled release |
| container_volume | 146 |
| creator | Moghimi, S.M. Andersen, A.J. Hashemi, S.H. Lettiero, B. Ahmadvand, D. Hunter, A.C. Andresen, T.L. Hamad, I. Szebeni, J. |
| description | Since their introduction, poly(ethylene glycol)–phospholipid (PEG–PL) conjugates have found many applications in design and engineering of nanosized delivery systems for controlled delivery of pharmaceuticals especially to non-macrophage targets. However, there are reports of idiosyncratic reactions to certain PEG–PL engineered nanomedicines in both experimental animals and man. These reactions are classified as pseudoallergy and may be associated with cardiopulmonary disturbance and other related symptoms of anaphylaxis. Recent studies suggest that complement activation may be a contributing, but not a rate limiting factor, in eliciting hypersensitivity reactions to such nanomedicines in sensitive individuals. This is rather surprising since PEGylated structures are generally assumed to suppress protein adsorption and blood opsonization events including complement. Here, we examine the molecular basis of complement activation by PEG–PL engineered nanomedicines and carbon nanotubes and discuss the challenges ahead.
This article examines the molecular basis of complement activation by PEG–lipid engineered nanomedicines and other entities (e.g., PEGylated carbon nanotubes), highlighting the role of PEG-PL interfaces in modulating the activity of complement system, and discuss the challenges ahead.
[Display omitted] |
| doi_str_mv | 10.1016/j.jconrel.2010.04.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_754894050</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365910002579</els_id><sourcerecordid>748954260</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-744a25f38cd020486fb03c5018218307510748ba57661591185bd672ff654ac73</originalsourceid><addsrcrecordid>eNqFkcFu1DAURS1ERYfCJ4C8QawyfY7t2GGD0KgUpJHooqwtx3mZ8ShxBjtT1B3_wB_yJTjM0C67snR97vPzvYS8YbBkwKrL3XLnxhCxX5aQNRBLAP6MLJhWvBB1LZ-TReZ0wStZn5OXKe0AQHKhXpDzErjWsqwX5OdqHPY9Dhgmat3k7-zkx0CdTc62SKfoNxuM2NLmnt5cXf_59ftmTTFsfMB_crBhHLD1LguJ2tBma2zyhPliOjSYPtDbLVK3tX2ffTO0Rdu-Imed7RO-Pp0X5Pvnq9vVl2L97frr6tO6cKKspkIJYUvZce1aKEHoqmuAOwlMl0xzUJKBErqxUlUVkzVjWjZtpcquq6SwTvEL8v44dx_HHwdMkxl8ctj3NuB4SEZJoWsBEp4mMyjzUjMpj6SLY0oRO7OPfrDx3jAwczlmZ07lmLkcA8LkcrLv7emFQ5Mze3D9byMD707AHH_fRRucT48cZzUoPn_q45HDnNydx2iS8xhc7iGim0w7-idW-QvB7rAH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>748954260</pqid></control><display><type>article</type><title>Complement activation cascade triggered by PEG–PL engineered nanomedicines and carbon nanotubes: The challenges ahead</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Moghimi, S.M. ; Andersen, A.J. ; Hashemi, S.H. ; Lettiero, B. ; Ahmadvand, D. ; Hunter, A.C. ; Andresen, T.L. ; Hamad, I. ; Szebeni, J.</creator><creatorcontrib>Moghimi, S.M. ; Andersen, A.J. ; Hashemi, S.H. ; Lettiero, B. ; Ahmadvand, D. ; Hunter, A.C. ; Andresen, T.L. ; Hamad, I. ; Szebeni, J.</creatorcontrib><description>Since their introduction, poly(ethylene glycol)–phospholipid (PEG–PL) conjugates have found many applications in design and engineering of nanosized delivery systems for controlled delivery of pharmaceuticals especially to non-macrophage targets. However, there are reports of idiosyncratic reactions to certain PEG–PL engineered nanomedicines in both experimental animals and man. These reactions are classified as pseudoallergy and may be associated with cardiopulmonary disturbance and other related symptoms of anaphylaxis. Recent studies suggest that complement activation may be a contributing, but not a rate limiting factor, in eliciting hypersensitivity reactions to such nanomedicines in sensitive individuals. This is rather surprising since PEGylated structures are generally assumed to suppress protein adsorption and blood opsonization events including complement. Here, we examine the molecular basis of complement activation by PEG–PL engineered nanomedicines and carbon nanotubes and discuss the challenges ahead.
This article examines the molecular basis of complement activation by PEG–lipid engineered nanomedicines and other entities (e.g., PEGylated carbon nanotubes), highlighting the role of PEG-PL interfaces in modulating the activity of complement system, and discuss the challenges ahead.
[Display omitted]</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2010.04.003</identifier><identifier>PMID: 20388529</identifier><identifier>CODEN: JCREEC</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>Anaphylaxis - chemically induced ; Animals ; Antibiotics, Antineoplastic - adverse effects ; Antibiotics, Antineoplastic - immunology ; Biological and medical sciences ; Carbon nanotube ; Complement Activation ; Doxorubicin - adverse effects ; Doxorubicin - immunology ; General pharmacology ; Humans ; Liposome ; Medical sciences ; Micelle ; Nanostructures - administration & dosage ; Nanostructures - adverse effects ; Nanotubes, Carbon - adverse effects ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Phospholipids - adverse effects ; Phospholipids - metabolism ; Poly(ethylene glycol) ; Polyethylene Glycols - adverse effects ; Polyethylene Glycols - metabolism ; Pseudoallergy ; Serum - drug effects ; Serum - immunology ; Swine</subject><ispartof>Journal of controlled release, 2010-09, Vol.146 (2), p.175-181</ispartof><rights>2010 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright 2010 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c426t-744a25f38cd020486fb03c5018218307510748ba57661591185bd672ff654ac73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0168365910002579$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,3537,23909,23910,25118,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23190737$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20388529$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moghimi, S.M.</creatorcontrib><creatorcontrib>Andersen, A.J.</creatorcontrib><creatorcontrib>Hashemi, S.H.</creatorcontrib><creatorcontrib>Lettiero, B.</creatorcontrib><creatorcontrib>Ahmadvand, D.</creatorcontrib><creatorcontrib>Hunter, A.C.</creatorcontrib><creatorcontrib>Andresen, T.L.</creatorcontrib><creatorcontrib>Hamad, I.</creatorcontrib><creatorcontrib>Szebeni, J.</creatorcontrib><title>Complement activation cascade triggered by PEG–PL engineered nanomedicines and carbon nanotubes: The challenges ahead</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>Since their introduction, poly(ethylene glycol)–phospholipid (PEG–PL) conjugates have found many applications in design and engineering of nanosized delivery systems for controlled delivery of pharmaceuticals especially to non-macrophage targets. However, there are reports of idiosyncratic reactions to certain PEG–PL engineered nanomedicines in both experimental animals and man. These reactions are classified as pseudoallergy and may be associated with cardiopulmonary disturbance and other related symptoms of anaphylaxis. Recent studies suggest that complement activation may be a contributing, but not a rate limiting factor, in eliciting hypersensitivity reactions to such nanomedicines in sensitive individuals. This is rather surprising since PEGylated structures are generally assumed to suppress protein adsorption and blood opsonization events including complement. Here, we examine the molecular basis of complement activation by PEG–PL engineered nanomedicines and carbon nanotubes and discuss the challenges ahead.
This article examines the molecular basis of complement activation by PEG–lipid engineered nanomedicines and other entities (e.g., PEGylated carbon nanotubes), highlighting the role of PEG-PL interfaces in modulating the activity of complement system, and discuss the challenges ahead.
[Display omitted]</description><subject>Anaphylaxis - chemically induced</subject><subject>Animals</subject><subject>Antibiotics, Antineoplastic - adverse effects</subject><subject>Antibiotics, Antineoplastic - immunology</subject><subject>Biological and medical sciences</subject><subject>Carbon nanotube</subject><subject>Complement Activation</subject><subject>Doxorubicin - adverse effects</subject><subject>Doxorubicin - immunology</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>Liposome</subject><subject>Medical sciences</subject><subject>Micelle</subject><subject>Nanostructures - administration & dosage</subject><subject>Nanostructures - adverse effects</subject><subject>Nanotubes, Carbon - adverse effects</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Phospholipids - adverse effects</subject><subject>Phospholipids - metabolism</subject><subject>Poly(ethylene glycol)</subject><subject>Polyethylene Glycols - adverse effects</subject><subject>Polyethylene Glycols - metabolism</subject><subject>Pseudoallergy</subject><subject>Serum - drug effects</subject><subject>Serum - immunology</subject><subject>Swine</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFu1DAURS1ERYfCJ4C8QawyfY7t2GGD0KgUpJHooqwtx3mZ8ShxBjtT1B3_wB_yJTjM0C67snR97vPzvYS8YbBkwKrL3XLnxhCxX5aQNRBLAP6MLJhWvBB1LZ-TReZ0wStZn5OXKe0AQHKhXpDzErjWsqwX5OdqHPY9Dhgmat3k7-zkx0CdTc62SKfoNxuM2NLmnt5cXf_59ftmTTFsfMB_crBhHLD1LguJ2tBma2zyhPliOjSYPtDbLVK3tX2ffTO0Rdu-Imed7RO-Pp0X5Pvnq9vVl2L97frr6tO6cKKspkIJYUvZce1aKEHoqmuAOwlMl0xzUJKBErqxUlUVkzVjWjZtpcquq6SwTvEL8v44dx_HHwdMkxl8ctj3NuB4SEZJoWsBEp4mMyjzUjMpj6SLY0oRO7OPfrDx3jAwczlmZ07lmLkcA8LkcrLv7emFQ5Mze3D9byMD707AHH_fRRucT48cZzUoPn_q45HDnNydx2iS8xhc7iGim0w7-idW-QvB7rAH</recordid><startdate>20100901</startdate><enddate>20100901</enddate><creator>Moghimi, S.M.</creator><creator>Andersen, A.J.</creator><creator>Hashemi, S.H.</creator><creator>Lettiero, B.</creator><creator>Ahmadvand, D.</creator><creator>Hunter, A.C.</creator><creator>Andresen, T.L.</creator><creator>Hamad, I.</creator><creator>Szebeni, J.</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QO</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope></search><sort><creationdate>20100901</creationdate><title>Complement activation cascade triggered by PEG–PL engineered nanomedicines and carbon nanotubes: The challenges ahead</title><author>Moghimi, S.M. ; Andersen, A.J. ; Hashemi, S.H. ; Lettiero, B. ; Ahmadvand, D. ; Hunter, A.C. ; Andresen, T.L. ; Hamad, I. ; Szebeni, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-744a25f38cd020486fb03c5018218307510748ba57661591185bd672ff654ac73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Anaphylaxis - chemically induced</topic><topic>Animals</topic><topic>Antibiotics, Antineoplastic - adverse effects</topic><topic>Antibiotics, Antineoplastic - immunology</topic><topic>Biological and medical sciences</topic><topic>Carbon nanotube</topic><topic>Complement Activation</topic><topic>Doxorubicin - adverse effects</topic><topic>Doxorubicin - immunology</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>Liposome</topic><topic>Medical sciences</topic><topic>Micelle</topic><topic>Nanostructures - administration & dosage</topic><topic>Nanostructures - adverse effects</topic><topic>Nanotubes, Carbon - adverse effects</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Phospholipids - adverse effects</topic><topic>Phospholipids - metabolism</topic><topic>Poly(ethylene glycol)</topic><topic>Polyethylene Glycols - adverse effects</topic><topic>Polyethylene Glycols - metabolism</topic><topic>Pseudoallergy</topic><topic>Serum - drug effects</topic><topic>Serum - immunology</topic><topic>Swine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moghimi, S.M.</creatorcontrib><creatorcontrib>Andersen, A.J.</creatorcontrib><creatorcontrib>Hashemi, S.H.</creatorcontrib><creatorcontrib>Lettiero, B.</creatorcontrib><creatorcontrib>Ahmadvand, D.</creatorcontrib><creatorcontrib>Hunter, A.C.</creatorcontrib><creatorcontrib>Andresen, T.L.</creatorcontrib><creatorcontrib>Hamad, I.</creatorcontrib><creatorcontrib>Szebeni, J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moghimi, S.M.</au><au>Andersen, A.J.</au><au>Hashemi, S.H.</au><au>Lettiero, B.</au><au>Ahmadvand, D.</au><au>Hunter, A.C.</au><au>Andresen, T.L.</au><au>Hamad, I.</au><au>Szebeni, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Complement activation cascade triggered by PEG–PL engineered nanomedicines and carbon nanotubes: The challenges ahead</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2010-09-01</date><risdate>2010</risdate><volume>146</volume><issue>2</issue><spage>175</spage><epage>181</epage><pages>175-181</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><coden>JCREEC</coden><abstract>Since their introduction, poly(ethylene glycol)–phospholipid (PEG–PL) conjugates have found many applications in design and engineering of nanosized delivery systems for controlled delivery of pharmaceuticals especially to non-macrophage targets. However, there are reports of idiosyncratic reactions to certain PEG–PL engineered nanomedicines in both experimental animals and man. These reactions are classified as pseudoallergy and may be associated with cardiopulmonary disturbance and other related symptoms of anaphylaxis. Recent studies suggest that complement activation may be a contributing, but not a rate limiting factor, in eliciting hypersensitivity reactions to such nanomedicines in sensitive individuals. This is rather surprising since PEGylated structures are generally assumed to suppress protein adsorption and blood opsonization events including complement. Here, we examine the molecular basis of complement activation by PEG–PL engineered nanomedicines and carbon nanotubes and discuss the challenges ahead.
This article examines the molecular basis of complement activation by PEG–lipid engineered nanomedicines and other entities (e.g., PEGylated carbon nanotubes), highlighting the role of PEG-PL interfaces in modulating the activity of complement system, and discuss the challenges ahead.
[Display omitted]</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>20388529</pmid><doi>10.1016/j.jconrel.2010.04.003</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-3659 |
| ispartof | Journal of controlled release, 2010-09, Vol.146 (2), p.175-181 |
| issn | 0168-3659 1873-4995 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_754894050 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Anaphylaxis - chemically induced Animals Antibiotics, Antineoplastic - adverse effects Antibiotics, Antineoplastic - immunology Biological and medical sciences Carbon nanotube Complement Activation Doxorubicin - adverse effects Doxorubicin - immunology General pharmacology Humans Liposome Medical sciences Micelle Nanostructures - administration & dosage Nanostructures - adverse effects Nanotubes, Carbon - adverse effects Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Phospholipids - adverse effects Phospholipids - metabolism Poly(ethylene glycol) Polyethylene Glycols - adverse effects Polyethylene Glycols - metabolism Pseudoallergy Serum - drug effects Serum - immunology Swine |
| title | Complement activation cascade triggered by PEG–PL engineered nanomedicines and carbon nanotubes: The challenges ahead |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T06%3A03%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Complement%20activation%20cascade%20triggered%20by%20PEG%E2%80%93PL%20engineered%20nanomedicines%20and%20carbon%20nanotubes:%20The%20challenges%20ahead&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Moghimi,%20S.M.&rft.date=2010-09-01&rft.volume=146&rft.issue=2&rft.spage=175&rft.epage=181&rft.pages=175-181&rft.issn=0168-3659&rft.eissn=1873-4995&rft.coden=JCREEC&rft_id=info:doi/10.1016/j.jconrel.2010.04.003&rft_dat=%3Cproquest_cross%3E748954260%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=748954260&rft_id=info:pmid/20388529&rft_els_id=S0168365910002579&rfr_iscdi=true |